Design of a Novel Fab‐Like Antibody Fragment with Enhanced Stability and Affinity for Clinical use

Wang, Chunyu; Hong, Jiaxu; Yang, Zhenlin; Zhou, Xujiao; Yang, Yuhan; Yu, Ker‐Wei; Chen, Binfan; Wu, Huifang; Qian, Bin‐Zhi; Dimitrov, Dimiter S.; Zhou, Xingtao; Wu, Yanling; Ying, Tianlei

doi:10.1002/smtd.202100966

Cited by 1 publication

(1 citation statement)

References 55 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fab agents are the oldest class of mAb fragment therapeutics. Several Fab products have already been approved by the US Food and Drug Administration (FDA) for clinical use (certolizumab pegol, ranibizumab, abciximab, and idarucizumab) [24,25]. They contain one constant and one variable heavy and light chain domain, respectively.…”

Section: Comparison Of Nanobody ® Molecules With Other Types Of Thera...mentioning

confidence: 99%

NANOBODY® Molecule, a Giga Medical Tool in Nanodimensions

Kunz,

Durandy,

Seguin

et al. 2023

IJMS

View full text Add to dashboard Cite

Although antibodies remain the most widely used tool for biomedical research, antibody technology is not flawless. Innovative alternatives, such as Nanobody® molecules, were developed to address the shortcomings of conventional antibodies. Nanobody® molecules are antigen-binding variable-domain fragments derived from the heavy-chain-only antibodies of camelids (VHH) and combine the advantageous properties of small molecules and monoclonal antibodies. Nanobody® molecules present a small size (~15 kDa, 4 nm long and 2.5 nm wide), high solubility, stability, specificity, and affinity, ease of cloning, and thermal and chemical resistance. Recombinant production in microorganisms is cost-effective, and VHH are also building blocks for multidomain constructs. These unique features led to numerous applications in fundamental research, diagnostics, and therapy. Nanobody® molecules are employed as biomarker probes and, when fused to radioisotopes or fluorophores, represent ideal non-invasive in vivo imaging agents. They can be used as neutralizing agents, receptor-ligand antagonists, or in targeted vehicle-based drug therapy. As early as 2018, the first Nanobody®, Cablivi (caplacizumab), a single-domain antibody (sdAb) drug developed by French pharmaceutical giant Sanofi for the treatment of adult patients with acquired thrombocytopenic purpura (aTTP), was launched. Nanobody® compounds are ideal tools for further development in clinics for diagnostic and therapeutic purposes.

show abstract

Section: Comparison Of Nanobody ® Molecules With Other Types Of Thera...mentioning

confidence: 99%